About: Bempegaldesleukin
An Entity of Type: chemical substance,
from Named Graph: http://dbpedia.org,
within Data Space: dbpedia.org
Bempegaldesleukin (development code NKTR-214) is an experimental anti-cancer drug candidate. It is a PEGylated interleukin-2 (IL-2) acting as a CD122-preferential IL-2 pathway agonist designed to activate and proliferate CD8+ T cells and NK cells. It is being developed by Nektar Therapeutics. In August 2019 the FDA granted breakthrough therapy designation to bempegaldesleukin in combination with nivolumab for the treatment of advanced melanoma. It is in phase 3 clinical trials for melanoma and renal cell carcinoma.
| Property | Value |
|---|---|
| dbo:abstract |
|
| dbo:casNumber |
|
| dbo:drugbank |
|
| dbo:fdaUniiCode |
|
| dbo:inn |
|
| dbo:kegg |
|
| dbo:wikiPageID |
|
| dbo:wikiPageLength |
|
| dbo:wikiPageRevisionID |
|
| dbo:wikiPageWikiLink |
|
| dbp:casNumber |
|
| dbp:drugbank |
|
| dbp:inn |
|
| dbp:kegg |
|
| dbp:unii |
|
| dbp:wikiPageUsesTemplate | |
| dcterms:subject | |
| rdf:type | |
| rdfs:comment |
|
| rdfs:label |
|
| owl:sameAs | |
| prov:wasDerivedFrom | |
| foaf:isPrimaryTopicOf | |
| is dbo:wikiPageRedirects of | |
| is dbo:wikiPageWikiLink of | |
| is foaf:primaryTopic of |
This content was extracted from Wikipedia and is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License